News Sentiment

KTTA sentiment intelligence

Pasithea Therapeutics Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.45 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

87/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-8.6% over one week, -10.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Pasithea Therapeutics (KTTA) Proxy filing Summary

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 87/100 classification
One-week reaction -8.6% Price reacting lower
Trend fit Trend inactive -10.0% over four weeks
Fair value -87.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 31
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 10
Market source 8
Stock Titan 7
GlobeNewswire 4
simplywall.st 4
MT Newswires 3
Quartr 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 12
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Quartr Direct company coverage

Pasithea Therapeutics (KTTA) Proxy filing Summary

Pasithea Therapeutics (KTTA) has released a summary of its proxy filing. The annual meeting, scheduled for September 3, 2025, will cover four key proposals including director elections, auditor ratification, an amendment to the 2023 Stock Incentive Plan, and a reverse stock split

Tone
Negative 36/100
Event
Market update
Published
21 Jul 2026 22:10
Source
Quartr
Quartr Direct company coverage

Pasithea Therapeutics (KTTA) Registration filing Summary

Pasithea Therapeutics (KTTA) is a clinical-stage biotechnology company focused on treatments for CNS disorders, RASopathies, MAPK pathway-driven tumors, and other diseases. The company reported net losses of $13.9 million in 2024 and $16.0 million in 2023, with an accumulated def

Tone
Negative 36/100
Event
Market update
Published
21 Jul 2026 21:42
Source
Quartr
Quiver Quantitative Direct company coverage

Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors

Pasithea Therapeutics Corp. announced that its Phase 1 dose-escalation study for PAS-004, a macrocyclic MEK inhibitor, has been accepted for a poster presentation at the ESMO Congress 2026 on October 23. The study focuses on the safety and pharmacokinetics of PAS-004 in patients

Tone
Positive 62/100
Event
Market update
Published
21 Jul 2026 11:39
Source
Quiver Quantitative
Stock Titan Direct company coverage

Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot

Pasithea Therapeutics (NASDAQ: KTTA) announced that its Phase I dose-escalation study data for PAS-004, a next-generation oral macrocyclic MEK inhibitor, in MAPK pathway-driven advanced solid tumors has been accepted for a poster presentation at the ESMO Congress 2026. The presen

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 10:39
Source
Stock Titan
GlobeNewswire Direct company coverage

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Pasithea Therapeutics announced that data from its Phase 1 dose-escalation study of PAS-004, a macrocyclic MEK inhibitor, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will detail the safety and pharmacokinetics of PAS-004 f

Tone
Positive 65/100
Event
Market update
Published
21 Jul 2026 07:00
Source
GlobeNewswire
Sahm Direct company coverage

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Pasithea Therapeutics Corp. announced its management will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The clinical-stage biotechnology company, focused on developing PAS-004 for chronic diseases and neurofibromatosis type 1, wi

Tone
Positive 66/100
Event
Market update
Published
09 Jul 2026 07:12
Source
Sahm
Pluang Direct company coverage

Pasithea Therapeutics to present at B. Riley Mi...

Pasithea Therapeutics, a clinical-stage biotech company developing PAS-004 for chronic diseases like neurofibromatosis type 1, will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. This summit offers an opportunity for Pasithea to e

Tone
Positive 67/100
Event
Market update
Published
08 Jul 2026 11:10
Source
Pluang
Stock Titan Direct company coverage

Pasithea management to meet investors at B. Riley health summit in Boston

Pasithea Therapeutics (NASDAQ: KTTA) announced its management will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The clinical-stage biotech, focusing on its lead drug candidate PAS-004 for chronic diseases including NF1, will eng

Tone
Positive 61/100
Event
Market update
Published
08 Jul 2026 11:10
Source
Stock Titan
TradingView Direct company coverage

Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings

This page provides access to Pasithea Therapeutics Corp.'s financial disclosures and SEC filings, including quarterly and annual reports (10-Q and 10-K forms). Investors can use these documents to evaluate the company's financial performance and operational updates. The filings s

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 00:40
Source
TradingView
Stock Titan Direct company coverage

Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed

Coastlands Capital LP and its affiliated entities, along with Matthew D. Perry, have disclosed a beneficial ownership of 3,835,035 shares, representing an 11.48% stake in Pasithea Therapeutics (KTTA). This information comes from a Schedule 13G/A SEC filing, indicating a passive i

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Jul 2026 00:40
Source
Stock Titan
Bitget Direct company coverage

Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies.

Pasithea Therapeutics Corp. has announced that its drug candidate, Pas-4, exhibited a favorable safety profile in clinical studies, with all observed adverse events being grade 1 or 2. This positive safety data is crucial for the drug's continued clinical development and potentia

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 15:09
Source
Bitget
grafa.com Direct company coverage

Pasithea reports positive PAS-004 Phase 1 cancer data

Pasithea Therapeutics announced positive interim Phase 1 data for its oral MEK inhibitor, PAS-004, in patients with advanced MAPK pathway-driven solid tumors. The study revealed a favorable safety profile and instances of disease stabilization exceeding six months in heavily pret

Tone
Positive 87/100
Event
Market update
Published
30 Jun 2026 14:09
Source
grafa.com
GlobeNewswire Direct company coverage

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Pasithea Therapeutics announced positive interim Phase 1 data for its drug candidate PAS-004 in advanced cancer patients, demonstrating favorable long-term safety and durable clinical activity, particularly in MEK/BRAF-pretreated individuals. The company noted that PAS-004 has be

Tone
Positive 91/100
Event
Market update
Published
30 Jun 2026 11:09
Source
GlobeNewswire
Stock Titan Direct company coverage

Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens

Pasithea Therapeutics announced positive interim Phase 1 data for PAS-004 in advanced cancer patients, showing favorable safety and durable disease stabilization. The oral MEK inhibitor demonstrated strong tolerability, with all adverse events being Grade 1–2, and pharmacokinetic

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 11:09
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA

This article focuses on the enterprise value to revenue forward metric for Pasithea Therapeutics Corp. (NASDAQ: KTTA). It is a brief financial snippet from TradingView, highlighting a specific valuation ratio for the company. The content appears to be a stub or a section of a lar

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 19:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA

This article displays the "Price to book forward" financial metric for Pasithea Therapeutics Corp. (NASDAQ: KTTA) on TradingView. It appears to be a stub or a data point within a larger financial platform, showing the value and changes for this specific financial indicator over a

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 06:42
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA

This article provides a brief financial overview of Pasithea Therapeutics Corp. (NASDAQ: KTTA), focusing on its price-to-sales forward metric. It indicates that the market was closed at the time of publication and that there were no trades. The article is sourced from TradingView

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Pasithea Therapeutics Corp. – BOATS:KTTAW

The article focuses on the "Price to sales forward" metric for Pasithea Therapeutics Corp. (KTTAW) on the Blue Ocean Alternative Trade System (BOATS). It notes that the market was closed and there were no trades recorded for this specific financial indicator. The content is prima

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – BOATS:KTTAW

This article provides the enterprise value to revenue forward for Pasithea Therapeutics Corp. (KTTAW), as presented on TradingView. It notes that the market is closed with no trades. The content primarily shows navigation elements and disclaimers rather than financial data.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA)

This article provides key financial data and analyst estimates for Pasithea Therapeutics Corp. (NASDAQ:KTTA). It covers current stock performance, historical highs and lows, future price forecasts from analysts, and upcoming earnings dates, alongside other company financials and

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings

This article provides a comprehensive list of Pasithea Therapeutics Corp.'s SEC filings and other financial documents, including annual 10-K and quarterly 10-Q reports, dating back to 2021. It also lists corporate events such as conference participations. The information aims to

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 05:10
Source
TradingView
Investing.com South Africa Direct company coverage

Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com

This article announces the filing of a Form 13G for Pasithea Therapeutics Corp. on June 23. It reminds readers that trading in financial instruments and cryptocurrencies involves significant risks and that data on Investing.com may not be real-time or accurate.

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 03:10
Source
Investing.com South Africa
Investing.com Nigeria Direct company coverage

Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com

This article announces the filing of a Form 4 for Pasithea Therapeutics Corp on June 22nd, as reported by Investing.com. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a co

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 15:40
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com

Coastlands Capital LP, a significant shareholder in Pasithea Therapeutics Corp., recently acquired 100,000 shares of the company's common stock for $53,000 at $0.53 per share. This transaction increases their indirect holdings to 3,835,035 shares, occurring after the stock experi

Tone
Positive 66/100
Event
Market update
Published
22 Jun 2026 14:39
Source
Investing.com Nigeria
TradingKey Direct company coverage

Pasithea Therapeutics Corp (KTTA) Institutional Confidence

This article provides an overview of Pasithea Therapeutics Corp (KTTA)'s institutional confidence, highlighting the institutional shareholding. It lists several key institutional investors and their respective shareholdings in the company. The data indicates that the institutiona

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 17:40
Source
TradingKey